Active TopicsActive Topics  Display List of Forum MembersMemberlist  CalendarCalendar  Search The ForumSearch  HelpHelp
  RegisterRegister  LoginLogin

Value buys - The intrinsic value is close to market price
 The Equity Desk Forum :Investment Ideas - Creating winning portfolios! :Value buys - The intrinsic value is close to market price
Message Icon Topic: Wockhardt - NAV distressed price deep value Post Reply Post New Topic
Page  of 6 Next >>
Author Message
excel_monkey
Senior Member
Senior Member
Avatar

Joined: 17/Nov/2009
Online Status: Offline
Posts: 1281
Quote excel_monkey Replybullet Topic: Wockhardt - NAV distressed price deep value
    Posted: 26/Jun/2010 at 5:41pm
I have tried to do the NAV of Wockhardt
I think at current valuation it is quoting at a deep discount to its NAV
 
NAV of Wockhardt
 
 
Rs. Crore
Assets
 
 
 
 
Sales
Multiple
Value 
India formulations
934
4
3737
APIs and generics
1,462
1.5
2193
Overseas formulations
1,222
1
1222
Total assets
 
 
7152
 
 
 
 
Liabilities
 
 
 
Estimated debt
 
 
3600
Forex losses
 
 
400
Cash with company
 
 
200
Total Liabilities
 
 
3800
 
 
 
 
 
 
 
 
NAV (assets - Liabilities)
 
 
3352
NAV per share (Rs)
 
 
306
Current share price (Rs)
 
 
138
Potential upside
 
 
122%
 
The underlying business is still making healthy profit (EBITDA of 800 crore) and is very much viable
 
The domestic formulations business has been conservatively valued at 4 times the sales as opposed to Piramal business which was sold at 9 times the sales.
 
The forex losses are in excess of 800 crores but these are just the claims from the banks (Barclays etc) as the banks terminated the contracts when the rates were in their favour and I think no way the company is not going to pay the full amount (so there would be a litigation for 400 crores).
 
Other benefits which I have not included are the benefits and breaks which the company will get under the CDR (Debt restructuring)
 
Most of the figures are estimates and have been derived from different sources so have a margin of error of (+) (-) 10%
 
 
IP IP Logged
studentoflife
Senior Member
Senior Member
Avatar

Joined: 06/Mar/2009
Online Status: Offline
Posts: 313
Quote studentoflife Replybullet Posted: 26/Jun/2010 at 6:55pm
Check the contingent liability of the company over the years:
Contingent liabilities 1,448.51 1,219.81 1,369.37 93.74 6.30
This doesnt seem to be good trend ...with loans of about 1500 crores.
 
What if these contingencies need to be exercised..wouldnt the company go bankrupt...?
 
IP IP Logged
excel_monkey
Senior Member
Senior Member
Avatar

Joined: 17/Nov/2009
Online Status: Offline
Posts: 1281
Quote excel_monkey Replybullet Posted: 26/Jun/2010 at 7:06pm
most of the contingent liability is related to forex losses which have not yet crystallized.
and some of the contingent liability is related to forex losses which have been slapped on the company by banks who have cancelled the derivatives contracts citing the company's fccb default.


I don't think that these liabilities are real liabilities they are just the worst case scenario liabilities.
I have taken a cash out flow of Rs. 400 crore for such liabilities in my NAV
IP IP Logged
excel_monkey
Senior Member
Senior Member
Avatar

Joined: 17/Nov/2009
Online Status: Offline
Posts: 1281
Quote excel_monkey Replybullet Posted: 26/Jun/2010 at 7:14pm
Please also go through this BW article
 
A Bumpy Road To Nowhere?

Wockhardt’s revival is up against unanswered questions and tricky lawsuits

By

On 31 March, Mumbai-based pharmaceutical company Wockhardt’s bid to claw its way out of a near-impossible situation received a rude jolt. US drug maker Abbott terminated its decision to acquire its nutrition business for $140 million. “Abbott and Wockhardt jointly made this decision because Wockhardt was unable to resolve debt restructuring issues with some of its lenders,” said a terse statement from the US company.  

Things had begun to stabilise for the Rs 3,600-crore Wockhardt. A majority of its lenders agreed in June to a corporate debt restructuring (CDR) process for the hugely indebted company including fresh terms for holders of $110 million worth foreign currency convertible bonds (FCCBs) that it defaulted on in October. Wockhardt agreed to key asset sales — including that of the nutrition business — to raise funds. Controlling stakeholder Habil Khorakiwala sold off most of his hospital business, which was also making demands on the group’s resources, to New Delhi’s Fortis Healthcare. The company began negotiating with banks to settle derivatives contracts that had backfired when currency markets swung the other way. “The management has been able to take all the pressure quite effectively,” says Nimish Mehta, pharma analyst at Vadodara-based MP Advisors. “And it hasn’t sold any of its crown jewels (in the company).”  

But this looks like it could come to nought. Since October, Wockhardt is defending itself in court against a group of unsecured lenders who want it wound up. The lenders, foreign banks and institutions including holders of 40 per cent of FCCBs, are up in arms against the CDR. Seven winding-up petitions have been filed so far, just two have been settled out-of-court, and news reports suggest more could be on the way.  

For a start, the lawsuits have successfully nixed the Abbott deal by blocking it in court and effectively, any other asset sale that Wockhardt wants to conclude in the future. “We are willing to fight for as long as it takes,” says one bondholder, who spoke on condition of anonymity. “We have won judgements in our favour even after five years.” 

The timing could not have been worse. The debt moratorium comes to an end this July. In parallel, analysts reckon that derivatives losses are in the hundreds of crores. In the meantime, the business, which has been fairly resilient, is showing signs of strain. 

Legal Wrangles
Foreign banks and institutions were not party to Wockhardt’s CDR, a voluntary process to restructure debt of troubled companies that banks believe to be viable. The CDR was led by ICICI Bank and included banks such as SBI. The CDR, agreed to on 30 June, put a moratorium on all repayments for a year, sanctioned priority debt, and gave Wockhardt access to working capital loans. It also offered new terms to bondholders which SBI, holding about 60 per cent of the bonds, accepted (see ‘Testing The Bond’).

But the foreign banks and institutions are in no mood to bite. They see the CDR as a lopsided package favourable to secured, domestic lenders.  Barclays Bank, Calyon Bank, and the BNY Corporate Trustee Services (representing the bondholders) have filed separate petitions in the Bombay High Court seeking injunctions. “There is no transparency in the CDR document on how discounts for the FCCB holders and foreign banks were arrived at,” claims a person close to the petitioners. “The discounts on loans and repayment schedules are different for the two sides.”

In addition to extending term loans, Barclays and Calyon also entered into derivative contracts with Wockhardt, which is now disputing the amounts owed. (Barclays declined to comment and Calyon did not respond to an email.) The petitioners objected to the sale of Wockhardt’s nutrition business unless the proceeds, including a non-compete fee meant for Khorakiwala, were deposited in a ‘no-lien’ account. This is to prevent secured lenders being paid off through asset sales leaving the petitioners with little or nothing. The CDR requires Wockhardt to raise money through asset sale. “How can an unsecured creditor ask a secured one to surrender its rights and interests on its security?” asks one person close to Wockhardt, who was present at the hearings. The petitioners also want the court to appoint a provisional liquidator for the company.
Majmudar & Co., representing Wockhardt, and Juris Corp., which is either advising or representing the various petitioners, declined to comment citing the matter as sub-judice. An ICICI spokesperson says the bank “does not comment on client-specific issues”. Khorakiwala did not meet BW for this article. A spokesperson cited the ‘silent period’ before Wockhardt’s results, as the reason. So far Wockhardt has settled only with the Development Bank of Singapore, which was the first to sue in October last year. Since then, its shares had lost 15 per cent at the time of writing while BSE’s Healthcare Index gained 22 per cent.
Lenders to Wockhardt’s overseas subsidiaries were reportedly evaluating going to court too. 

Game Of Bluff?
On 22 February, bondholder QVT, a $9-billion New York-headquartered fund floated what it called an alternative restructuring plan for Wockhardt outside the court proceedings. The plan envisages giving bondholders new bonds that will mandatorily be converted into equity shares (instead of preference shares) in Wockhardt upon maturity. So far, Wockhardt has said nothing. QVT is one of the bondholders that has gone to court. So its new plan, claims the source close to Wockhardt, is an indicator that some of the petitioners still see the company as viable. “Or else why would they want equity,” he asks. The winding-up petition, he believes, is merely a pressure tactic to bring Wockhardt to the negotiating table. After all, he points out, if the company does get liquidated they will still have to queue up behind the secured debtors.
TESTING THE BOND 
WHAT IS ON OFFER FOR FCCB HOLDERS IN THE CORPORATE DEBT RESTRUCTURING
  • Buyback at 65 per cent discount, or
  • Issuance of preference shares partly convertible into equity in 2015 and partly redeemed in 2018 with coupon rate of less than 1 per cent
WHAT A SECTION OF FCCB HOLDERS HAVE PROPOSED
  • Issuance at a ratio of 1.295 new FCCBs for every defaulted bond
  • Mandatory conversion into Wockhardt equity shares at dilution
  • Conversion price at a premium to company share price on the maturity date of defaulted bonds
  • A semi-annual coupon of 5 per cent
*FCCB: Foreign Currency Convertible Bond
True, it will not be an easy fight for the lenders. For one, the secured lenders have agreed to CDR. Mehta of MP Advisors points out that Indian courts have been reluctant to issue winding-up orders against companies of this size and scale if there is any chance of their revival. The CDR, which has the sanction of the Reserve Bank of India, is meant for just that, he says. “We expect that bondholders will settle (once they get a judgement from the court),” he says. He does not expect Wockhardt to be wound up.  

Recent history does throw up some examples where courts have ruled in favour of unsecured lenders in winding-up petitions. Last September, the Madras High Court admitted such a petition against beleaguered retailer Subhiksha. This March, the Bombay High Court reportedly declared Indage Vintners as a fit case for winding up. In the case of Subhiksha, the CDR process hit a dead end, while in the case of Indage, unsecured creditors reportedly went to court even before the CDR was completed, citing a lack of faith in the process.  

Scratching The Surface
The termination of the Abbott deal has damaged Wockhardt’s fragile recovery plan. The lawsuits could put off future buyers, who are interested in other parts of Wockhardt’s business. 

In the meantime, in addition to servicing term loans, the company needs cash to settle substantial claims on derivatives. Mehta of MP Advisors calculates total derivative liabilities of Rs 1,300 crore including amounts that will be settled at a steep discount or converted into preference shares.  

But it is not just lawsuits standing in the way of Wockhardt’s recovery. For one, analysts are still unsure of exactly how much of derivatives liability will be written off, and at what point. The company has bought time by extending its financial year to 15 months ending 31 March 2010 as it moves to evaluate the extent of its exposure and negotiates with banks to settle. 

Wockhardt’s track record in sharing information on this front is also dubious. In March 2008, the company told the BSE that it will not incur losses “either this time or in the future from hedged positions”. Last quarter alone, it wrote off Rs 235 crore.  

It is this opacity that spooked equity analysts even before the legal tangle. Sarabjit Kour Nangra, vice-president, research at Mumbai-based Angel Broking stopped tracking Wockhardt mid last year and says there is no reason to start now. “There’s too much uncertainty and too little transparency,” she says. For instance, she can’t understand why Wockhardt posted mark-to-market losses last quarter even when companies such as Ranbaxy have recorded gains on the back of a strengthening rupee. 

It could get worse. Wockhardt’s operations are facing challenges. For instance, a French subsidiary faces the threat of patent expiry on a key product representing a chunk of sales. An Irish subsidiary suffered from a price cut by the government. In the last quarter, sales were down by 9 per cent while gross profit was down by 35 per cent partly on account of the sale of its veterinary and German unit, but also owing to pressures in Europe.  

Besides, there is little or no funding for growth plans. As a result, small, but high-potential businesses such as biotechnology are just treading water. “We don’t think the debt restructuring will hamper the base business,” says Mehta. “But you can’t expect the company to grow for the next three to four years.”  

The secured lenders, in the meantime, will also be under pressure if the CDR cannot be made to work. Will this force them to take drastic measures like forcing an ownership or management change? Either way, Wockhardt’s road to recovery promises to be a long and arduous one. With no guarantee that it will get there.

gauri dot kamath at abp dot in
  
 
IP IP Logged
hit2710
Senior Member
Senior Member
Avatar

Joined: 15/Jun/2009
Location: India
Online Status: Offline
Posts: 4013
Quote hit2710 Replybullet Posted: 26/Jun/2010 at 8:14pm
Hi
I also used to follow wockhardt mainly based on technicals. Can you compare the formulations valutions with some other companies besides piramal? say something like ajanta or cadilla or unichem if possible?
regards,
hitesh.
Stockmarket is a weird place. For every person who buys a stock there is a person who sells it and both think they are very smart.
IP IP Logged
excel_monkey
Senior Member
Senior Member
Avatar

Joined: 17/Nov/2009
Online Status: Offline
Posts: 1281
Quote excel_monkey Replybullet Posted: 26/Jun/2010 at 8:25pm
Originally posted by hit2710

Hi
I also used to follow wockhardt mainly based on technicals. Can you compare the formulations valutions with some other companies besides piramal? say something like ajanta or cadilla or unichem if possible?
regards,
hitesh.


I recently read a report but am unable to locate it
Amongst all the companies covered Unichem was the cheapest based on EV/formulations sales ratio (at EV/S of 2)

Ajanta was not part of the study
IP IP Logged
excel_monkey
Senior Member
Senior Member
Avatar

Joined: 17/Nov/2009
Online Status: Offline
Posts: 1281
Quote excel_monkey Replybullet Posted: 26/Jun/2010 at 8:49pm
I think Torrent Pharma could also be a good sell-off bet as the promoters would like to focus more on power business going forward
IP IP Logged
excel_monkey
Senior Member
Senior Member
Avatar

Joined: 17/Nov/2009
Online Status: Offline
Posts: 1281
Quote excel_monkey Replybullet Posted: 27/Jun/2010 at 3:29pm
I haven't found a single person who is bullish on Wockhart
and that makes me more bullish on the stock
I get a kick when everyone disagrees with my opinion
it kind of indicates the under ownership

Originally posted by studentoflife

Check the contingent liability of the company over the years:

<TABLE =Table>
<T>
<TR>
<TD>Contingent liabilities</TD>
<TD =numericalColumn>1,448.51</TD>
<TD =numericalColumn>1,219.81</TD>
<TD =numericalColumn>1,369.37</TD>
<TD =numericalColumn>93.74</TD>
<TD =numericalColumn>6.30</TD></TR></T></TABLE>


This doesnt seem to be good trend ...with loans of about 1500 crores.

 

What if these contingencies need to be exercised..wouldnt the company go bankrupt...?

 
IP IP Logged
Page  of 6 Next >>
Post Reply Post New Topic
Printable version Printable version

Forum Jump
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot delete your posts in this forum
You cannot edit your posts in this forum
You cannot create polls in this forum
You cannot vote in polls in this forum



This page was generated in 0.109 seconds.
Bookmark this Page

Join Theequitydesk.com Today!

It’s easy to Join and it’s free.

Here's why members would love to be a part of theequitydesk.com

  • Equity Desk focuses on why to buy shares and invest in share rather than what to buy.
  • Live discussion forum wherein members can discuss the current Indian share Market trend, BSE Sensex or the Nifty Index.
  • Have huge cache of information on Indian and World Share Market.
  • Analysis of Indian stock market, Global events, Investing insights, portfolio management strategies and thoughts,
  • Meet investors from round the globe check their investing strategies share experiences and learn for their experiences on stocks and shares, evaluate opinions on investing in India.

Register now while it’s free!

Already a member? Close this window and log in.

Join Us           Close